Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Approximately 7% of participants in the Phase 2 clinical trial experienced skin sensitivity, compared to 1% in the placebo group
TESTIMONIALS OTHER OPTIONS ANTIOXIDANT DRIP - This vitamin IV infusion is a powerful way to detox your system and reduce the harmful effects of oxidation and inflammation
While traditional sharps containers may be too bulky for travel, compact versions are available and are suitable for short trips
Luca Busetto, PhD , can be reached at [email protected].
Glenn Lyle offers a modern, non-invasive solution for women looking to improve early signs of neck aging
Back to Journals Drug, Healthcare and Patient Safety Volume 18 Adverse Events Associated with Tirzepatide: Updated Pharmacovigilance Analysis Using FAERS (2022 Q1-2025 Q1) with an Adapted Time-to-Onset Method Authors Gu S Received 29 July 2025 Accepted for publication 3 January 2026 Published 8 January 2026 Volume 2026:18 556918 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 3 Editor who approved publication: Professor Siew Siang Chua Saisai Gu Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Peoples Republic of China Correspondence: Saisai Gu, Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Peoples Republic of China, Email [email protected] Purpose: Tirzepatide, the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with rapidly expanding clinical use, requires detailed post-marketing pharmacovigilance to monitor emerging safety signals
